** Shares of vaccine maker Novavax NVAX.O rise 13% to $7.06 premarket
** Co says its COVID-19 vaccine is "approvable based on conversations with the U.S. Food and Drug Administration (FDA)"
** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval
** The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month
** Up to last close, stock had fallen 22.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.